Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation

NCT01671605 | Completed Results DMC

• 1 other identifier: 090846
• Study Type: observational
• Target: 103
• Locations: 1 country
• Sites: 1

Brief Summary

There is currently little understanding of macrophage cholesterol homeostasis and foam cell formation across the spectrum of CKD. We hypothesize that an inverse relationship exist between the severity of CKD and processes underlying foam cell formation, and that the relationship becomes independent of serum lipoprotein levels as renal function declines. We propose to systematically examine scavenger receptors and cholesterol uptake as well as cholesterol transporters and efflux mechanisms in individuals with normal renal function, patients with moderate CKD. We further propose to determine if processed contributing to foam cell formation are related to the plasma lipid profile and if the relationship is modified by co-morbidities, such as diabetes, obesity, systemic inflammation which are common in this population and directly influence vascular integrity. These data will be critically important to understand when the abnormality starts and will provide crucial information.

Conditions

Chronic Kidney Disease; Cardiovascular Disease

Outcome Measures

Primary Outcomes (1)

• In Vitro Lipoprotein Functions

  Cholesterol efflux. Baseline and outcome measurements are the same. The cholesterol efflux was measured once using HDL isolated from CKD and control patients. There was no intervention,this assessment was performed once in each group. The measurement of cholesterol efflux is performed by an in vitro assay in cultured cells. Cells are loaded with cholesterol and maintained for 72 hours. The media of the cultured cells is then changed and the new media contains HDL from CKD or control patients. In additional cells, no HDL is added. The cells are maintained for 24 hours, and intracellular cholesterol is assessed. The cholesterol efflux represents the amount of cholesterol that was leached by HDL from each of our study groups. Thus, cells not exposed to any HDL will contain the highest intracellular cholesterol content. The amount of cholesterol in cells exposed to CKD HDL or control HDL reflects the efflux capacity of that HDL. This is expressed as percent of cholesterol removed by HDL.

  Once, at enrollment

Study Arms (2)

CKD not on dialysis

Patients with CKD not on dialysis (CKD III-IV)

Controls

Controls with normal kidney function (Control)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with CKD not on dialysis (CKD III-IV) Controls with normal kidney function (Control)

You may qualify if:

• Patients with moderate degree of CKD, or patients with advanced CKD or control subjects with intact kidney function
• Male or female
• All ethnic groups
• ≥ 18 years and have signed informed consent

You may not qualify if:

• Pregnancy and current smoking
• BMI \> 45
• Rheumatoid arthritis and systemic lupus erythematosus
• History of active or chronic hepatitis B, history of active or chronic hepatitis C, human immunodeficiency virus (HIV)
• For moderate CKD subjects: nephrotic syndrome
• For control subjects: nephrotic syndrome, patients with estimated GFR \< 60 mL/min/1.73 m\^2, or proteinuria

Sponsors & Collaborators

• Vanderbilt University Medical Center: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Vanderbilt Outpatient Dialysis Center

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Valentina Kon
• Organization: Vanderbilt University Medical Center

valentina.kon@vanderbilt.edu

6153224883

Study Officials

• Valentina Kon, MD

  Vanderbilt University Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 20, 2012
• First Posted: August 23, 2012
• Study Start: February 1, 2013
• Primary Completion: April 1, 2015
• Study Completion: April 1, 2015
• Last Updated: April 21, 2017
• Results First Posted: April 21, 2017

Record last verified: 2017-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)